Synergistic inhibition of PARP-1 and NF-κB signaling downregulates immune response against recombinant AAV2 vectors during hepatic gene therapy
Open accessAbstract
Host immune response remains a key obstacle to widespread application of adeno‐associated virus (AAV) based gene therapy. Thus, targeted inhibition of the signaling pathways that trigger such immune responses will be beneficial. Previous studies have reported that DNA damage response proteins such as poly(ADP‐ribose) polymerase‐1 (PARP‐1) negatively affect the integration of AAV in the host genome. However, the role of PARP‐1 in regulating AAV transduction and the immune response against these vectors has not been elucidated. In this study, we demonstrate that repression of PARP‐1 improves the transduction of single‐stranded AAV vectors both in vitro (∼174%) and in vivo (two‐ to 3.4‐fold). Inhibition of PARP‐1, also significantly downregulated the expression of several proinflammatory and cytokine markers such as TLRs, ILs, NF‐κB subunit proteins associated with the host innate response against self‐complementary AAV2 vectors. The suppression of the inflammatory response targeted against these vectors was more effective upon combined inhibition of PARP‐1 and NF‐κB signaling. This strategy also effectively attenuated the AAV capsid‐specific cytotoxic T‐cell response, with minimal effect on vector transduction, as demonstrated in normal C57BL/6 and hemophilia B mice. These data suggest that targeting specific host cellular proteins could be useful to attenuate the immune barriers to AAV‐mediated gene therapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
PARP-1 inhibition can attenuate the AAV capsid-directed cytotoxic T cell response, downregulate TLR and NF-kB expression, and improve the transduction efficiency of AAV vectors by three-fold in the liver.
“Moreover, PARP-1 inhibition can attenuate the AAV capsid-directed cytotoxic T cell response, downregulate TLR and NF-kB expression, and improve the transduction efficiency of AAV vectors by three-fold in the liver (Hareendran et al., 2016).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Hareendran et al., 2016
The Discussion reports that PARP-1 inhibition downregulated TLRs and NF-κB-related inflammatory factors. The transduction-results section reports increased liver expression in mice, but the increase was about 3.4-fold for ssAAV8 and twofold for ssAAV2, not threefold for AAV vectors generally. The cytotoxic T-cell-results section attributes the reduced capsid-specific response to combined PARP-1 and NF-κB inhibition, not PARP-1 inhibition alone. (LLM, conf=0.90)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
Jayandharan, G. R., Aslanidi, G., Martino, A. T., Jahn, S. C., Perrin, G. Q., Herzog, R. W., & Srivastava, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012753108 · Cited by 72 · see citing works
Self-citationRetractedThe immunopathogenesis of sepsis
Cohen, J. (2002) · Nature · doi:10.1038/nature01326 · Cited by 2,742 · see citing works
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · see citing works
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · see citing works
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · see citing works
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · see citing works
Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB
Beg, A. A., Sha, W. C., Bronson, R. T., Ghosh, S., & Baltimore, D. (1995) · Nature · doi:10.1038/376167a0 · Cited by 1,828 · see citing works
Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions
D’Amours, D., Desnoyers, S., D’Silva, I., & Poirier, G. G. (1999) · Biochemical Journal · doi:10.1042/bj3420249 · Cited by 1,819 · see citing works
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273 · see citing works
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors
Jagtap, P. G., & Szabó, C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1718 · Cited by 896 · see citing works
NF-κB as a Therapeutic Target in Multiple Myeloma
Hideshima, T., Chauhan, D., Richardson, P. G. G., Mitsiades, C. S., Mitsiades, N., Hayashi, T., Munshi, N. C., Dang, L., Castro, A. C., Palombella, V. J., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200360200 · Cited by 894 · see citing works
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893 · see citing works
Gene therapy clinical trials worldwide to 2012 – an update
Ginn, S., Alexander, I. E., Edelstein, M. L., Abedi, M. R., & Wixon, J. (2013) · Journal of Gene Medicine · doi:10.1002/jgm.2698 · Cited by 807 · see citing works
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · see citing works
Chambon, P., Weill, J. D., & Mandel, P. (1963) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(63)90024-x · Cited by 654 · see citing works
Transcriptional Activation by NF-κB Requires Multiple Coactivators
Sheppard, K.-A., Rose, D. W., Haque, Z. K., Kurokawa, R., McInerney, E. M., Westin, S. K., Thanos, D., Rosenfeld, M. G., Glass, C. K., & Collins, T. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.6367 · Cited by 430 · see citing works
Hassa, P. O., & Hottiger, M. O. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-002-8527-2 · Cited by 428 · see citing works
Hassa, P. O., Haenni, S. S., Buerki, C., Meier, N. I., Lane, W. S., Owen, H., Gersbach, M., Imhof, R., & Hottiger, M. O. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507553200 · Cited by 306 · see citing works
The Enzymatic and DNA Binding Activity of PARP-1 Are Not Required for NF-κB Coactivator Function
Hassa, P. O., Covic, M., Hasan, S., Imhof, R., & Hottiger, M. O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106528200 · Cited by 296 · see citing works
Mingozzi, F., Meulenberg, J. J., Hui, D. J., Basner-Tschakarjan, E., Hasbrouck, N. C., Edmonson, S. A., Hutnick, N. A., Betts, M. R., Kastelein, J. J., Stroes, E. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-167510 · Cited by 295 · see citing works
Roebuck, K. A., Rahman, A., Lakshminarayanan, V., Janakidevi, K., & Malik, A. B. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.32.18966 · Cited by 282 · see citing works
Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina
Petrs-Silva, H., Dinculescu, A., Li, Q., Deng, W.-T., Pang, J.-J., Min, S.-H., Chiodo, V., Neeley, A. W., Govindasamy, L., Bennett, A., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.234 · Cited by 267 · see citing works
Self-citationMartino, A. T., Suzuki, M., Markusic, D. M., Zolotukhin, I., Ryals, R. C., Moghimi, B., Ertl, H. C. J., Muruve, D. A., Lee, B., & Herzog, R. W. (2011) · Blood · doi:10.1182/blood-2010-10-314518 · Cited by 246 · see citing works
Abdelkarim, G. E., Gertz, K. R., Harms, C., Katchanov, J., Dirnagl, U., Szabó, C., & Endres, M. (2001) · International Journal of Molecular Medicine · doi:10.3892/ijmm.7.3.255 · Cited by 241 · see citing works
A review of PARP inhibitors: from bench to bedside
Underhill, C. R., Toulmonde, M., & Bonnefoi, H. R. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq322 · Cited by 241 · see citing works
Hassa, P. O., Buerki, C., Lombardi, C., Imhof, R., & Hottiger, M. O. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307957200 · Cited by 236 · see citing works
Berenson, J. R., Yang, H. H., Sadler, K., Jarutirasarn, S. G., Vescio, R. A., Mapes, R., Purner, M. B., Lee, S.-P., Wilson, J., Morrison, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2383 · Cited by 209 · see citing works
Vision 1 Year after Gene Therapy for Leber's Congenital Amaurosis
Cideciyan, A. V., Hauswirth, W. W., Alemán, T. S., Kaushal, S., Schwartz, S., Boye, S. L., Windsor, E. A. M., Conlon, T. J., Sumaroka, A., Román, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0903652 · Cited by 199 · see citing works
Ludwig, H., Khayat, D., Giaccone, G., & Facon, T. T. F. (2005) · Cancer · doi:10.1002/cncr.21414 · Cited by 179 · see citing works
Proteasome inhibitors in the treatment of multiple myeloma
Shah, J. J., & Orlowski, R. Z. (2009) · Leukemia · doi:10.1038/leu.2009.173 · Cited by 178 · see citing works
Regulation of microglial expression of integrins by poly(ADP-ribose) polymerase-1
Ullrich, O., Diestel, A., Eyüpoglu, I. Y., & Nitsch, R. (2001) · Nature Cell Biology · doi:10.1038/ncb1201-1035 · Cited by 175 · see citing works
Poly(ADP-Ribose) Polymerase in the Cellular Response to DNA Damage, Apoptosis, and Disease
Oliver, F. J., Murcia, J. M., & de MURCIA, G. (1999) · The American Journal of Human Genetics · doi:10.1086/302389 · Cited by 156 · see citing works
Martín‐Oliva, D., Aguilar‐Quesada, R., O’Valle, F., Muñoz‐Gámez, J. A., Martínez‐Romero, R., del Moral, R. G., de Almodóvar, J. M. R., Villuendas, R., Piris, M. A., & Oliver, F. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3050 · Cited by 138 · see citing works
Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisited
Lupo, B., & Trusolino, L. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.07.004 · Cited by 131 · see citing works
Monahan, P. E., Lothrop, C. D., Sun, J., Hirsch, M. L., Kafri, T., Kantor, B., Sarkar, R., Tillson, D. M., Elia, J. R., & Samulski, R. J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.170 · Cited by 125 · see citing works
Hareendran, S., Balakrishnan, B., Sen, D., Kumar, S., Srivastava, A., & Jayandharan, G. R. (2013) · Reviews in Medical Virology · doi:10.1002/rmv.1762 · Cited by 113 · see citing works
Self-citationMowat, F. M., Gornik, K. R., Dinculescu, A., Boye, S. L., Hauswirth, W. W., Petersen-Jones, S. M., & Bartoe, J. T. (2014) · Gene Therapy · doi:10.1038/gt.2013.64 · Cited by 108 · see citing works
Regulation of Transcription Factor NFAT by ADP-Ribosylation
Olabisi, O. A., Soto-Nieves, N., Nieves, E., Yang, T. T. C., Yang, X., Yu, R. Y.-L., Suk, H. Y., Macián, F., & Chow, C.-W. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01746-07 · Cited by 104 · see citing works
Haddad, M., Rhinn, H., Bloquel, C., Coqueran, B., Szabó, C., Plotkine, M., Scherman, D., & Margaill, I. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706837 · Cited by 100 · see citing works
Juvekar, A., Manna, S., Ramaswami, S., Chang, T., Vu, H.-Y. T., Ghosh, C. C., Celiker, M., & Vancurova, I. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0368 · Cited by 96 · see citing works
DNA-dependent PK inhibits adeno-associated virus DNA integration
Song, S., Lu, Y., Choi, Y., Han, Y., Tang, Q., Zhao, G., Berns, K. I., & Flotte, T. R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307833100 · Cited by 94 · see citing works
Gabriel, N., Hareendran, S., Sen, D., Gadkari, R. A., Sudha, G., Selot, R., Hussain, M., Dhaksnamoorthy, R., Samuel, R., Srinivasan, N., et al. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.194 · Cited by 90 · see citing works
Self-citationPARP inhibitors: New tools to protect from inflammation
Giansanti, V., Donà, F., Tillhon, M., & Scovassi, A. I. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.04.022 · Cited by 85 · see citing works
Cervelli, T., Palacios, J. A., Zentilin, L., Mano, M., Schwartz, R. A., Weitzman, M. D., & Giacca, M. (2008) · Journal of Cell Science · doi:10.1242/jcs.003632 · Cited by 84 · see citing works
Gao, G., Lü, Y., Sun, X., Johnston, J., Calcedo, R., Grant, R. L., & Wilson, J. M. (2006) · Journal of Virology · doi:10.1128/jvi.00526-06 · Cited by 78 · see citing works
Scott, G. S., Kean, R. B., Mikheeva, T., Fabis, M. J., Mabley, J. G., Szabó, C., & Hooper, D. C. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.063214 · Cited by 78 · see citing works
Muthumani, K., Choo, A. Y., Zong, W., Madesh, M., Hwang, D. S., Arumugam, P., Thieu, K. P., Emmanuel, J., Kumar, S., Thompson, C. B., et al. (2006) · Nature Cell Biology · doi:10.1038/ncb1352 · Cited by 78 · see citing works
Determination of Specific CD4 and CD8 T Cell Epitopes after AAV2- and AAV8-hF.IX Gene Therapy
Chen, J., Wu, Q., Yang, P., Hsu, H., & Mountz, J. D. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.10.006 · Cited by 76 · see citing works
Oumouna, M., Datta, R., Oumouna‐Benachour, K., Suzuki, Y., Hans, C. P., Matthews, K., Fallon, K. B., & Boulares, H. A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.9.6489 · Cited by 75 · see citing works
Ohsaki, E., Ueda, K., Sakakibara, S., Do, E., Yada, K., & Yamanishi, K. (2004) · Journal of Virology · doi:10.1128/jvi.78.18.9936-9946.2004 · Cited by 71 · see citing works
McIntosh, J. H., Cochrane, M., Cobbold, S., Waldmann, H., Nathwani, S. A., Davidoff, A. M., & Nathwani, A. C. (2012) · Gene Therapy · doi:10.1038/gt.2011.64 · Cited by 70 · see citing works
Unzu, C., Hervás-Stubbs, S., Sampedro, A., Mauleón, I., Mancheño, U., Alfaro, C., de Salamanca, R. E., Benito, A., Beattie, S. G., Petry, H., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-122 · Cited by 69 · see citing works
Kelkar, S., De, B. P., Gao, G., Wilson, J. M., Crystal, R. G., & Leopold, P. L. (2006) · Journal of Virology · doi:10.1128/jvi.00481-06 · Cited by 67 · see citing works
Wu, T., Töpfer, K., Lin, S.-W., Li, H., Bian, A., Zhou, X. Y., High, K. A., & Ertl, H. C. (2012) · Molecular Therapy · doi:10.1038/mt.2011.280 · Cited by 66 · see citing works
Regulation of Epstein-Barr Virus OriP Replication by Poly(ADP-Ribose) Polymerase 1
Tempera, I., Deng, Z., Atanasiu, C., Chen, C., D’Erme, M., & Lieberman, P. M. (2010) · Journal of Virology · doi:10.1128/jvi.02333-09 · Cited by 63 · see citing works
Transcriptional regulation by Poly(ADP-ribose) polymerase-1 during T cell activation
Saenz, L., Lozano, J. J., Valdor, R., Baroja‐Mazo, A., Ramı́rez, P., Parrilla, P., Aparício, P., Sumoy, L., & Yélamos, J. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-171 · Cited by 57 · see citing works
Jog, N. R., Dinnall, J.-A., Gallucci, S., Madaio, M. P., & Caricchio, R. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803565 · Cited by 51 · see citing works
Poly (ADP‐ribose) polymerases (PARPs) 1‐3 regulate astrocyte activation
Phulwani, N. K., & Kielian, T. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05403.x · Cited by 51 · see citing works
Sen, D., Gadkari, R. A., Sudha, G., Gabriel, N., Kumar, Y. S., Selot, R., Samuel, R., Rajalingam, S., Ramya, V., Nair, S. C., et al. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.195 · Cited by 51 · see citing works
Self-citationQuantitative DNA slot blot analysis: inhibition of DNA binding to membranes by magnesium ions
Kube, D. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.16.3375 · Cited by 49 · see citing works
Activation of the Cellular Unfolded Protein Response by Recombinant Adeno-Associated Virus Vectors
Balakrishnan, B., Sen, D., Hareendran, S., Roshini, V., David, S., Srivastava, A., & Jayandharan, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053845 · Cited by 44 · see citing works
Self-citationMartínez‐Romero, R., Martínez‐Lara, E., Aguilar‐Quesada, R., Peralta, A., Oliver, F. J., & Siles, E. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21781 · Cited by 40 · see citing works
Effect of inhibition of dynein function and microtubule-altering drugs on AAV2 transduction
Hirosue, S., Senn, K., Clément, N., Nonnenmacher, M. E., Gigout, L. I., Linden, R. M., & Weber, T. (2007) · Virology · doi:10.1016/j.virol.2007.05.009 · Cited by 34 · see citing works
Ling, C., Lu, Y., Cheng, B., McGoogan, K. E., Gee, S. W. Y., Ma, W., Li, B., Aslanidi, G., & Srivastava, A. (2011) · Journal of Visualized Experiments · doi:10.3791/2538 · Cited by 32 · see citing works
Li, H., Tuyishime, S., Wu, T.-L., Giles‐Davis, W., Zhou, D., Xiao, W., High, K. A., & Ertl, H. C. J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.267 · Cited by 30 · see citing works
Roesner, J. P., Vagts, D. A., Iber, T., Eipel, C., Vollmar, B., & Nöldge‐Schomburg, G. (2006) · Intensive Care Medicine · doi:10.1007/s00134-006-0335-y · Cited by 27 · see citing works
Kármán, J., Gumlaw, N., Zhang, J., Jiang, J.-L., Cheng, S. H., & Zhu, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034684 · Cited by 25 · see citing works
Effect of poly(ADP‐ribose) polymerase 1 on integration of the adeno‐associated viral vector genome
Romanova, L., Zacharias, J., Cannon, M., & Philpott, N. (2011) · Journal of Gene Medicine · doi:10.1002/jgm.1577 · Cited by 7 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Understanding specific functions of PARP-2: new lessons for cancer therapy.
Ali, S. O., Khan, F. A., Galindo-Campos, M. A., & Yélamos, J. (2016) · PubMed Central · Cited by 43 · see citing works
Maurya, S., Mary, B., & Jayandharan, G. R. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.164 · Cited by 27 · see citing works
Self-citationPurdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24 · see citing works
“Moreover, PARP-1 inhibition can attenuate the AAV capsid-directed cytotoxic T cell response, downregulate TLR and NF-kB expression, and improve the transduction efficiency of AAV vectors by three-fold in the liver (Hareendran et al., 2016).”
Selot, R., Arumugam, S., Mary, B., Cheemadan, S., & Jayandharan, G. R. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00441 · Cited by 20 · see citing works
Self-citationNotarte, K. I., Catahay, J. A., Macasaet, R., Liu, J., Velasco, J. V., Peligro, P. J., Vallo, J., Goldrich, N., Lahoti, L., Zhou, J., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29305 · Cited by 19 · see citing works
Quantitative phase gradient metrology using diffraction phase microscopy and deep learning
Vithin, A. V. S., & Gannavarpu, R. (2023) · Journal of the Optical Society of America A · doi:10.1364/josaa.482262 · Cited by 10 · see citing works
Eskiler, G. G., & Özkan, A. D. (2021) · Molecular Immunology · doi:10.1016/j.molimm.2021.12.007 · Cited by 9 · see citing works
Gene Therapy in India- Current Status
Thakur, N., Batra, P., Singh, K., & Gupta, P. (2020) · Annals of the National Academy of Medical Sciences (India) · doi:10.1055/s-0040-1712756 · Cited by 5 · see citing works
TTV Species Diversity as a Novel Biomarker of Immune Dysregulation in Aging
Novazzi, F., Spezia, P. G., Ferrante, F. D., Genoni, A. P., Grossi, P., Mancini, N., Malavolta, M., Balietti, M., Piacenza, F., Marcozzi, S., et al. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70656 · Cited by 4 · see citing works
Recent developments in gene therapy research in India
Selot, R., & Ghosh, A. (2024) · Journal of Biosciences · doi:10.1007/s12038-024-00423-0 · Cited by 3 · see citing works
- Authors
- Hareendran, S., Ramakrishna, B., & Jayandharan, G. R.
- Affiliations
- Christian Medical College, Vellore (IN)
- Corresponding author
- Jayandharan, Giridhara R.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2015-11-05
- Volume
- 46
- Issue
- 1
- Pages
- 154-166
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W1946287926
- Cited by
- 10
- References
- 68
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 2 · 2021: 1 · 2020: 1 · 2019: 1 · 2017: 1 · 2016: 1
- FWCI
- 0.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Department of Biotechnology, Ministry of Science and Technology, India (BT/03/IYBA/2010, IYBA/2010)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PARP1, NF-κB signaling, adeno-associated virus type 2, AAV gene therapy, host immune response, hepatic gene therapy, AAV transduction, innate immunity, TLRs, cytokines, cytotoxic T lymphocytes, hemophilia B, DNA damage response
- MeSH terms
- Poly (ADP-Ribose) Polymerase-1, Dependovirus, Animals, Hemophilia B, Disease Models, Animal, Drug Synergism, Enzyme Inhibitors, Enzyme-Linked Immunosorbent Assay, Genetic Vectors, HeLa Cells, Humans, Liver, Mice, Inbred BALB C, Mice, Inbred C57BL, Poly(ADP-ribose) Polymerases, Transduction, Genetic, Transfection, Blotting, Western, Genetic Therapy, Down-Regulation, NF-kappa B, Mice, Real-Time Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
